Last updated on April 2019

A Study to Investigate the Safety and Efficacy of ABBV-105 Alone or in Combination With Upadacitinib (ABBV-599 Combination) in Participants With Active Rheumatoid Arthritis.

Brief description of study

This is a phase 2 study to evaluate safety and efficacy of ABBV-105 and ABBV-599 (ABBV-105 plus upadacitinib) vs placebo on a background of conventional synthetic disease-modifying anti-rheumatic drugs (csDMARDS) for the treatment of signs and symptoms of Rheumatoid Arthritis (RA) at 12 weeks in biological disease-modifying anti-rheumatic drugs(bDMARD)-inadequate response (bDMARD-IR) or bDMARD-intolerant participants with moderately to severely active RA and to define optimal dose for further development.

Clinical Study Identifier: NCT03682705

Contact Investigators or Research Sites near you

Start Over

Valerius Medical Group /ID# 168123

Los Alamitos, CA United States
  Connect »

Millennium Research /ID# 167453

Ormond Beach, FL United States
  Connect »

BayCare Medical Group /ID# 170860

Saint Petersburg, FL United States
  Connect »

FL Med Clinic, PA /ID# 206279

Zephyrhills, FL United States
  Connect »

PRN of Kansas /ID# 167985

Wichita, KS United States
  Connect »

June DO, PC /ID# 170670

Lansing, MI United States
  Connect »

Dhmc /Id# 167476

Lebanon, NH United States
  Connect »

Health Research Oklahoma /ID# 167370

Oklahoma City, OK United States
  Connect »

Royal Victoria Infirmary, Newc /ID# 201976

Newcastle Upon Tyne, United Kingdom
  Connect »

Ocean Rheumatology /ID# 170673

Toms River, NJ United States
  Connect »

Recruitment Status: Open

Brief Description Eligibility Contact Research Team

Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.